These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15484967)

  • 21. Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers.
    Jandhyala R
    Pharmaceut Med; 2020 Apr; 34(2):127-134. PubMed ID: 32048216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicalization, markets and consumers.
    Conrad P; Leiter V
    J Health Soc Behav; 2004; 45 Suppl():158-76. PubMed ID: 15779472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gifts and influence: Conflict of interest policies and prescribing of psychotropic medications in the United States.
    King M; Bearman PS
    Soc Sci Med; 2017 Jan; 172():153-162. PubMed ID: 27856120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exposure of medical students to pharmaceutical marketing in primary care settings: frequent and influential.
    Sarikaya O; Civaner M; Vatansever K
    Adv Health Sci Educ Theory Pract; 2009 Dec; 14(5):713-24. PubMed ID: 19184498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors.
    Edwards D; Ballantyne A
    Intern Med J; 2009 Mar; 39(3):191-6. PubMed ID: 19383067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription drug samples--does this marketing strategy counteract policies for quality use of medicines?
    Groves KE; Sketris I; Tett SE
    J Clin Pharm Ther; 2003 Aug; 28(4):259-71. PubMed ID: 12911677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of marketing in pharmaceutical research and development.
    Calfee JE
    Pharmacoeconomics; 2002; 20 Suppl 3():77-85. PubMed ID: 12457428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical promotion and GP prescription behaviour.
    Windmeijer F; de Laat E; Douven R; Mot E
    Health Econ; 2006 Jan; 15(1):5-18. PubMed ID: 15945041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical starter samples.
    Teichman PG; Caffee AE
    J Am Board Fam Pract; 2002; 15(6):509-10. PubMed ID: 12463302
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of educational interventions and medical school policies on medical students' attitudes toward pharmaceutical marketing practices: a multi-institutional study.
    Kao AC; Braddock C; Clay M; Elliott D; Epstein SK; Filstead W; Hotze T; May W; Reenan J
    Acad Med; 2011 Nov; 86(11):1454-62. PubMed ID: 21952057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Teaching appropriate interactions with pharmaceutical company representatives: the impact of an innovative workshop on student attitudes.
    Wofford JL; Ohl CA
    BMC Med Educ; 2005 Feb; 5(1):5. PubMed ID: 15698480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why lunch matters: assessing physicians' perceptions about industry relationships.
    Fugh-Berman AJ; Scialli AR; Bell AM
    J Contin Educ Health Prof; 2010; 30(3):197-204. PubMed ID: 20872775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does brand differentiate pharmaceuticals?
    Bednarik J
    Neuro Endocrinol Lett; 2005 Dec; 26(6):635-52. PubMed ID: 16380705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicians, pharmaceutical sales representatives, and the cost of prescribing.
    Caudill TS; Johnson MS; Rich EC; McKinney WP
    Arch Fam Med; 1996 Apr; 5(4):201-6. PubMed ID: 8769907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?
    Habibi R; Lexchin J; Mintzes B; Holbrook A
    Br J Clin Pharmacol; 2017 Nov; 83(11):2549-2556. PubMed ID: 28664660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An insider's perspective: defense of the pharmaceutical industry's marketing practices.
    Johar K
    Albany Law Rev; 2012-2013; 76(1):299-334. PubMed ID: 23577377
    [No Abstract]   [Full Text] [Related]  

  • 38. Prescription tracking and public health.
    Fugh-Berman A
    J Gen Intern Med; 2008 Aug; 23(8):1277-80. PubMed ID: 18473146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experts' agency problems: evidence from the prescription drug market in Japan.
    Iizuka T
    Rand J Econ; 2007; 38(3):844-62. PubMed ID: 18478669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaceutical promotion, advertising, and consumers.
    Batchlor E; Laouri M
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-109-11. PubMed ID: 14527240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.